The headline finding is that catastrophizing stood out as the strongest psychological predictor of pain intensity, even after the researchers statistically accounted for sex, cancer stage, cancer type, smoking, physical activity, analgesic use, and country. In the pooled sample of 200 patients, pain intensity correlated positively with catastrophizing with a Pearson coefficient of 0.53, a moderate-to-strong association in this field, while acceptance showed a negative correlation of −0.35. Intriguingly, acceptance and catastrophizing were themselves strongly inversely correlated at −0.59, suggesting these two constructs capture overlapping, largely opposite ways of appraising persistent pain.

The cross-national comparison added an unexpected layer. Lebanese participants reported significantly higher average pain intensity, 5.77 on an 11-point numeric scale versus 2.69 among Omani participants, along with markedly higher catastrophizing scores of 28.30 versus 14.55. Omani participants, meanwhile, reported substantially higher pain acceptance, at 61.79 versus 47.43. All of these differences were statistically significant, and the study’s explanatory regression model, which combined psychological, clinical, and demographic variables, accounted for roughly 44 percent of the variance in pain intensity, a substantial share for a construct as subjective and multidimensional as cancer pain.

Perhaps the most conceptually provocative result came from the exploratory mediation analysis. When the researchers used the PROCESS macro with 5,000 bootstrap samples to decompose the association between country and pain intensity, they found that catastrophizing statistically accounted for part of the gap. The total association between country and pain intensity was 3.08 points; adding catastrophizing to the model reduced the direct association to 1.85, leaving a significant indirect effect of 1.23 points flowing through the psychological variable. In plain terms, some of the difference in reported pain between the two countries traveled through differences in catastrophic thinking, although the authors are careful to stress that this is a statistical decomposition of group differences in cross-sectional data, not proof of a causal mechanism.

The theoretical scaffolding for these findings comes from the fear-avoidance model and the biopsychosocial model of pain. Catastrophizing, operationally measured by the 13-item Pain Catastrophizing Scale across three components of rumination, magnification, and helplessness, is thought to amplify perceived threat, bias attention toward pain signals, and fuel hypervigilance and avoidance, which in turn reinforce the chronic pain experience. Acceptance, grounded in psychological flexibility models and measured here by the Chronic Pain Acceptance Questionnaire with its activity engagement and pain willingness subscales, represents the opposite pole: acknowledging pain without futile control efforts while maintaining a functional life. The study’s instruments all showed strong psychometric properties in their validated Arabic versions, with internal consistency values ranging from roughly 0.83 to 0.94 in this sample.

Why, then, did acceptance fail to independently predict pain intensity in the adjusted regression despite its clear bivariate association? The authors point to conceptual overlap: because acceptance and catastrophizing are so strongly negatively correlated, the model cannot cleanly separate their contributions, and catastrophizing appears to be the more proximal cognitive amplifier of the raw sensory experience of pain. Acceptance, they argue, may exert its benefits primarily on broader outcomes such as psychological adjustment, physical functioning, and quality of life, rather than on pain intensity itself. That distinction carries real clinical weight, because it implies that interventions targeting catastrophic thinking might yield more direct reductions in perceived pain, while acceptance-based approaches like acceptance and commitment therapy may better improve how patients live with the pain they have.

The clinical profiles of the two samples differed in ways that complicate simple interpretation. Most Omani participants had hematological malignancies, 88 percent, often at unspecified stages, whereas 84 percent of Lebanese participants had solid tumors at more clearly documented stages. The Lebanese sample was older on average, 58.20 versus 43.58 years, more heavily represented by women, more likely to smoke, and more likely to report comorbidities and a family history of cancer. Notably, analgesic use emerged as a strong independent predictor of higher pain intensity, a relationship the authors attribute largely to reverse causation: patients in more pain are prescribed more medication. Yet even among analgesic users, pain remained clinically significant, echoing prior evidence that combined pharmacological strategies provide adequate relief in only about 70 percent of patients and can carry sedation, cognitive impairment, and dependence risks.

The country variable itself remained significant even after adjustment, pointing to contextual factors the study could not directly measure: differences in healthcare infrastructure, treatment access, disease burden at diagnosis, and sociocultural norms around expressing pain. Prior research in Oman has documented barriers to optimal cancer pain management, including fear of addiction, concerns about tolerance, and reluctance to report pain because of stigma. In Arab societies more broadly, sociocultural expectations may shape both how pain is communicated and which coping strategies, catastrophizing or acceptance, patients adopt. The authors argue that numeric pain scores should therefore be read within their sociocultural context rather than as pure biomedical indicators, and that cultural or systemic influences may shape cognitive appraisals that in turn color perceived intensity.

The practical implications are concrete. Because catastrophizing independently predicted pain severity, the authors recommend that oncology assessments look beyond intensity ratings to evaluate pain-related cognitions, and that structured psychological interventions, particularly cognitive-behavioral therapy, be integrated with pharmacological treatment. Meta-analytic evidence cited in the paper supports the value of cognitive-behavioral therapy for mental health and quality of life in cancer populations, and acceptance and commitment therapy has shown benefits for psychological flexibility, fatigue, sleep, and quality of life. A multidisciplinary model combining medical management with culturally sensitive, psychologically informed supportive care, the authors conclude, offers the best route to better pain control and less overreliance on medication.

The study’s limitations are worth keeping in view. The cross-sectional design precludes causal inference, self-reported measures are vulnerable to reporting biases shaped by cultural norms, and variables such as depression, anxiety, socioeconomic status, and healthcare access were not directly measured. The mediation finding is explicitly framed as exploratory. Still, as one of the first studies to simultaneously examine catastrophizing and acceptance in a cross-national Arab oncology sample, the work makes a compelling case that the mind’s appraisal of pain is not a footnote to cancer care but a modifiable target in its own right. The authors call for longitudinal and interventional studies to test whether reducing catastrophic thinking actually lowers perceived pain intensity, a question that, if answered affirmatively, could reshape supportive cancer care across diverse cultural settings.

Subject of Research: Psychological predictors of cancer pain intensity, including pain catastrophizing and pain acceptance, among patients in Oman and Lebanon

Article Title: Pain catastrophizing, pain acceptance, and pain intensity among patients with cancer in Oman and Lebanon: a comparative cross-sectional study

Article References: Hassan, J., Dankar, M., Al Azri, Z., Al Maskari, S., Al Senaidi, T., Al Maqbali, A., & Al Abri, B. (2026). Pain catastrophizing, pain acceptance, and pain intensity among patients with cancer in Oman and Lebanon: a comparative cross-sectional study. Supportive Care in Cancer, 34(10), Article 944. https://doi.org/10.1007/s00520-026-11191-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11191-y

Keywords: cancer pain, pain catastrophizing, pain acceptance, Oman, Lebanon, psycho-oncology, cross-sectional study, pain intensity, cognitive-behavioral therapy, biopsychosocial model, supportive care, Arab region

Cancer pain is extraordinarily common. According to a 2023 systematic review and meta-analysis cited in the report, the overall prevalence of pain among cancer patients is 44.5 percent, with roughly 30.6 percent experiencing moderate to severe pain. Among patients with advanced, metastatic, or end-stage disease, the prevalence climbs to 54.6 percent. Most of these patients achieve reasonable relief through oral or topical medications organized along the World Health Organization analgesic ladder. But an estimated 10 to 20 percent of those with moderate-to-severe cancer pain never obtain effective relief, or they abandon treatment because of intolerable side effects. These cases are defined as refractory cancer pain, and they represent a vicious physiological cycle in which persistent severe pain triggers central sensitization, placing the nervous system in a state of abnormally heightened and sustained sensitivity. Pain not only causes direct suffering but also amplifies its own signals through emotional and physiological mechanisms, elevating stress hormones, increasing cardiovascular demand, and impairing immune function, which may in turn accelerate disease progression.

The central technical argument of the new report is that traditional assessment tools are simply too narrow to capture this complexity. Clinicians have long relied on unidimensional instruments such as the numeric rating scale and the visual analogue scale, which reduce the entire pain experience to a single number, as well as on multidimensional questionnaires like the Brief Pain Inventory and neuropathic pain screening scales. All of these depend on patient subjectivity, which inherently biases the scores and can push treatment regimens away from optimal protocols. Neurophysiological testing offers objective data, but high equipment costs and technical complexity have limited its widespread clinical utility. The 6D BTS system was designed to fill this gap by combining multidimensional depth with objectivity and ease of use through a digital interface.

The Botong score comprises six dimensions. The first is the numeric rating scale itself, ranging from 0 for no pain to 10 for the worst pain imaginable, with scores of 1 to 3 reflecting mild pain, 4 to 6 moderate pain, and 7 to 10 severe pain. The second dimension assesses the impact of pain on physical function, with separate regional queries covering cervical spine, upper limb, lower back, and lower limb function, each scored from 0 for no impact to 10 for the most serious impact. The third and fourth dimensions measure the impact of pain on emotions and on sleep, using the same 0 to 10 range. The fifth dimension screens for neuropathic pain using the LANSS scale, in which affirmative responses to questions about needling stabbing pain, burning pain, tingling sensations, electric-shock-like pain, and pain exacerbated by touching clothes or sheets each add one point, while an affirmative response to a sixth question subtracts one point; scores of 2 to 3 suggest neuropathic pain and scores of 4 to 5 strongly suggest it. The sixth dimension assesses breakthrough pain, asking whether sudden, brief, unbearable severe pain occurs even when analgesics are otherwise controlling the baseline pain, including when body position changes.

Psychometric testing supports the instrument. Reliability analysis yielded a Cronbach’s alpha coefficient of 0.78 for the BTS, and validity analysis produced a KMO value of 0.80, indicating good reliability and construct validity. A randomized crossover trial published in Pain Therapeutics in 2023 compared the digital multidimensional Botong score with the Brief Pain Inventory for evaluating cancer-related pain and found the BTS could compensate for some of the BPI’s deficiencies. Notably, the BPI requires complex color-coding on body maps, a task frequently too difficult for elderly patients, whereas the BTS system employs voice-activated control and simplified queries to ensure accessibility. In the new case report, a robot equipped with the BTS 6D system visited the patient’s bedside, administered the questionnaire, and organized the results, remaining unaffected by healthcare staff and delivering standardized, objective scoring with a high detection rate.

The patient’s history illustrates why such comprehensive assessment matters. He had undergone laparoscopic cholecystectomy with extended radical resection and partial hepatectomy for gallbladder carcinoma in February 2022 at another hospital, where histopathology revealed moderately to well-differentiated adenocarcinoma invading the serosal layer with perineural invasion and metastases in both lymph nodes at the porta hepatis, staged T3N1Mx. Four cycles of oral capecitabine followed. In October 2022, clavicular metastasis was detected and treated with 25 sessions of localized radiotherapy. In May 2023, chest pain prompted imaging that suggested sternal metastasis, leading to another 25 radiotherapy sessions targeting the sternum plus two cycles of a GP chemotherapy regimen. Severe myelosuppression after each cycle forced discontinuation of further chemotherapy. Over the preceding year, his intermittent stabbing chest pain had escalated from self-managed codeine and ibuprofen to oxycodone extended-release tablets at 50 mg every 12 hours combined with pregabalin and celecoxib, with morphine suppositories for breakthrough episodes. In the five days before presentation, pain intensity surged, destroying his sleep and appetite.

On admission, the patient was cachectic with a Karnofsky Performance Status score of 60, confined to a forced supine position, with post-radiation hyperpigmentation across his chest, two firm palpable subcutaneous nodules roughly 2 cm in diameter, an enlarged tender lymph node in the right supraclavicular fossa, fine crackles in the right lung fields, and pitting edema in the lower extremities. His diagnoses included gallbladder carcinoma at stage IVB with multiple secondary bone, hepatic, pulmonary, and left adrenal malignancies, plus chronic refractory chest and back pain. The robot-assisted BTS evaluation localized his primary pain to the chest and back, characterized by stabbing and burning sensations, and quantified regional impact scores of 4 for the cervical spine, 3 for the upper limbs, 6 for the lumbar and dorsal regions, and 7 for the lower limbs. Sleep impact registered 9 and emotional impact 10. Screening identified a neuropathic pain component with a score of 3, and he reported six daily breakthrough episodes, significantly exacerbated by postural changes. In accordance with the 2017 Expert Consensus on Refractory Cancer Pain, the team designed a tailored multimodal analgesic regimen addressing this complex profile.

On January 3, 2024, the team initiated intravenous hydromorphone patient-controlled analgesia at a concentration of 0.6 mg/mL, with a basal rate of 1.3 mL/h, a 3.2 mL bolus, a 15-minute lockout interval, and an hourly limit of 10.9 mL. Baseline control was initially adequate, but three breakthrough episodes occurred within the first 12 hours. Titration on January 5 to a 1.5 mL/h basal rate and 3.6 mL bolus brought the NRS to 3 with three daily breakthrough episodes. By January 7, pain had rebounded to NRS 6 with six daily episodes occurring predominantly at night. The team added pregabalin and olanzapine and adjusted the PCA to a 2.5 mL/h basal rate and 4.5 mL bolus, achieving stable control at NRS 3 with only one daily episode. Critically, the BTS data identified the pain as classic incident pain triggered by movement or postural changes, so the patient was instructed to self-administer pre-emptive PCA boluses before physical activity. Laxatives and dietary modifications prevented opioid-induced constipation. By January 13, when he transferred to a local hospital continuing intravenous PCA, his NRS was 1 with no breakthrough episodes, and remote monitoring through the BTS digital health system confirmed stable analgesia at NRS 2 by January 20, with regional impact scores collapsing toward zero and the neuropathic component down to 1.

The patient’s own words capture what the numbers mean. Before treatment, he reported that his pain destroyed his will to live, and stated that his greatest fear was not death but dying in agony. After achieving adequate analgesia, he told the nursing staff that he could now say goodbye to his children without screaming in pain. The authors emphasize that the real harm of cancer pain lies not only in physical suffering but in the erosion of dignity and meaningful connection at the end of life. They also acknowledge important limitations: as the BTS is an assessment instrument, the observed analgesic benefit is attributable to the therapeutic regimen it informed rather than to the tool itself, and this single case cannot isolate the incremental contribution of multidimensional assessment over standard titration. The patient succumbed to disease progression one month after discharge, precluding long-term follow-up data.

Even so, the case demonstrates that multidimensional digital assessment proved feasible and provided clinically relevant information that may offer a foundation for hypothesis testing in subsequent controlled trials. The authors argue that investigations should now focus on full-cycle management and real-time surveillance of refractory pain, maximizing quality of life for cancer patients. If the 6D BTS system and its robotic interface can be validated at scale, the integration of artificial intelligence, standardized digital scoring, and remote dynamic monitoring could transform refractory cancer pain from an unmeasurable ordeal into a precisely quantified, continuously tracked, and effectively treated condition, offering patients the chance to spend their final months in comfort and connection rather than in agony.

Subject of Research: Digital pain assessment technology for refractory cancer pain management

Article Title: Case Report: Application of the 6D BTS digital assessment system in the comprehensive management of refractory cancer pain in a patient with gallbladder carcinoma

Article References: Ren, J., Li, Y., Zhou, K., Wang, Y., Wang, Q., Hu, D., Song, T., Dong, H., Cheng, Z., Hu, C., Huang, K., Zhang, Y., & Zhuang, L. (2026). Case Report: Application of the 6D BTS digital assessment system in the comprehensive management of refractory cancer pain in a patient with gallbladder carcinoma. Frontiers in Pain Research, 7, Article 1808441. https://doi.org/10.3389/fpain.2026.1808441

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1808441

Keywords: cancer pain, refractory cancer pain, digital health, pain assessment, gallbladder carcinoma, robotics, patient-controlled analgesia, palliative care, artificial intelligence, oncology, Case, Report

The scale of the problem the trial targets is difficult to overstate. Cancer patients and survivors experience pain at rates far exceeding those of the general population, and that pain erodes quality of life, disrupts sleep, fuels anxiety and depression, and can undermine the very treatments meant to cure or control the disease. Evidence-based, multi-modal pain care strategies, which combine pharmacologic approaches with behavioral, rehabilitative, and self-management techniques, already exist and are endorsed by clinical guidelines. Yet the authors of the ASCENT protocol point out that knowing what works is not the same as delivering it. Existing care models frequently fail to account for the preferences, support systems, and social needs of individual patients, and those failures fall hardest on populations facing structural barriers to access.

That is why the trial focuses specifically on rural-dwelling and/or Hispanic cancer patients with moderate to severe pain receiving care at one of eight participating sites. Rural patients often live hours from specialty pain services, and Hispanic patients may confront language barriers, distrust, and cost-related obstacles that make consistent follow-up nearly impossible. Social determinants of health, the economic and social conditions that shape a person’s ability to obtain care, are treated in ASCENT not as background noise but as a core clinical variable. The intervention is explicitly designed to identify and address these social determinant of health related access barriers alongside the pain itself, a dual mandate that distinguishes it from most prior pain management trials.

The mechanics of the intervention are deceptively simple. Participants randomized to the intervention arm receive a structured series of telephone and video calls over six months, delivered not by a physician but by a carefully constructed dyad: a Pain Care Manager paired with a Community Health Worker. The Pain Care Manager brings clinical expertise in pain assessment and management, while the Community Health Worker brings cultural connection, local knowledge, and the trust that comes from shared community experience. This pairing is the engine of the trial’s equity strategy. The community health worker can surface social needs that a patient might never disclose in a busy oncology clinic, from transportation problems to housing instability to difficulty affording medications, and can help translate the care plan into something that actually fits the patient’s life.

Each participant’s journey through the intervention begins with initial calls designed to characterize their pain and cancer histories, their management preferences, and their social determinant of health needs. From that assessment, the team constructs a Personalized Pain Management Program for each participant, one that is explicitly aligned both with the best available evidence and with the patient’s own stated preferences. The program is not a static document handed to the patient at discharge; it is refined during subsequent calls over the six-month period, allowing the dyad to adjust strategies as pain evolves, as side effects emerge, or as social circumstances shift. This iterative, preference-sensitive approach reflects a growing recognition in pain medicine that adherence depends less on the theoretical superiority of a treatment than on whether the patient actually wants and is able to follow it.

On the measurement side, the trial is rigorous and patient-centered. All participants, in both the intervention and control arms, complete outcome assessments at baseline and at three and six months. The battery captures pain, physical functioning, mood, sleep, quality of life, and pain catastrophizing, the pattern of catastrophic thinking about pain that is known to amplify suffering and disability. The primary outcome is pain itself, assessed with the Brief Pain Inventory, one of the most widely validated instruments in the field. Beyond patient-reported measures, the trial will track healthcare utilization outcomes, including hospitalizations and emergency care visits, providing a hard-edged test of whether better ambulatory pain management actually keeps patients out of emergency departments and hospital beds. That utilization data matters enormously for any future effort to scale the model, because payers and health systems will want evidence that proactive remote care offsets downstream acute care costs.

The theoretical scaffolding of the trial is the collaborative care model, an approach originally developed for depression treatment in primary care and since validated across dozens of chronic conditions. In its classic form, collaborative care embeds a care manager within a primary care team, supported by a consulting specialist who reviews cases and advises on treatment escalation. ASCENT adapts this architecture for cancer pain and strips away the requirement that patients physically travel to a clinic. By delivering the model entirely through telephone and video contact, the trial tests whether the collaborative care engine can run at a distance, reaching patients for whom the traditional clinic-based version is geographically or socially out of reach. If it works, the implications extend well beyond the two populations studied here, since the barriers faced by rural and Hispanic patients, distance, cost, language, and trust, are barriers that many other groups share.

The trial is supported by the National Institutes of Health through the NIH HEAL Initiative under award number R33CA278594, a funding stream created to accelerate solutions to the nation’s overlapping pain and opioid crises. That provenance is significant. Cancer pain management sits at a difficult intersection in American medicine: opioids remain an essential tool for many patients with moderate to severe cancer-related pain, yet the broader crackdown on opioid prescribing has made clinicians increasingly hesitant to prescribe, and patients with cancer have sometimes been caught in the crossfire of policies designed for other populations. A multi-modal, remotely delivered model that combines pharmacologic and non-pharmacologic strategies, monitors safety, and tailors care to individual preferences represents one plausible path through that thicket, offering comprehensive relief without relying on any single class of medication.

The research team itself reflects the trial’s community-embedded philosophy. In addition to investigators from Mayo Clinic sites in Rochester and Phoenix, the University of Oklahoma’s TSET Health Promotion Research Center and Stephenson Cancer Center, Yale University School of Medicine, Indiana University School of Medicine, the Regenstrief Institute, and The Ohio State University College of Medicine, the author list includes Deisy Canon Lovera of HACER, Hispanic Advocacy and Community Empowerment through Research, a St. Paul, Minnesota organization dedicated to community-driven research with Hispanic populations. The ASCENT Team consortium includes additional staff members who will carry out the day-to-day work of recruitment, assessment, and intervention delivery. The authors have also committed to a dissemination policy that extends beyond academic publication: findings will be shared at conferences and in peer-reviewed journals, and preliminary results will be sent to participants themselves in a final newsletter thanking them for their contribution, a small but meaningful gesture of reciprocity toward the patients whose data will drive the science.

For now, ASCENT remains a protocol rather than a result, and the oncology community will have to wait for the trial’s outcome data to know whether this model delivers. But the design alone signals where the field is heading. The future of cancer pain management, the trial suggests, may belong not to any single analgesic but to hybrid systems that pair clinical expertise with community trust, that treat social barriers as treatable clinical problems, and that meet patients where they are, literally, through the phone in their pocket. If the six-month intervention reduces pain, improves function and mood, and keeps patients out of emergency rooms, it would offer a potentially scalable, remote template for equitable pain care at a moment when the demand for such models has never been clearer.

Subject of Research: A randomized clinical trial protocol testing a digitally-enabled collaborative care intervention for cancer pain management in rural-dwelling and Hispanic patients

Article Title: Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain Management (ASCENT): Protocol for a Randomized Clinical Trial

Article References: Minteer, S. A., Austin, J. D., Clark, M. M., Morrison, E. J., Herrin, J., Tilburt, J., Pachman, D. R., Ruddy, K. J., Nelson, A., Podratz, J., Frick, M., Daus, L., Kroenke, K., Doubeni, C. A., Lovera, D. C., ASCENT Team, Dozois, D., Hein, J., Lulf, J., … Cheville, A. (2026). Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain Management (ASCENT): Protocol for a Randomized Clinical Trial. BMC Cancer. https://doi.org/10.1186/s12885-026-17122-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17122-8

Keywords: cancer pain, randomized clinical trial, collaborative care model, community health worker, telehealth, health equity, rural health, Hispanic health, social determinants of health, pain management, NIH HEAL Initiative, Mayo Clinic

Mellar P. Davis, a palliative oncologist at the Levine Cancer Institute of Atrium Health in Charlotte, North Carolina, does not call for abandoning scheduled dosing. Instead, his analysis weaves together experimental psychology, addiction neuroscience, and clinical prescribing data to advance a single candidate principle for opioid stewardship in cancer survivorship: whenever clinically feasible, opioid exposure should remain linked to meaningful symptom relief. The idea is that pain-contingent use, in which a dose follows the arrival of pain rather than the arrival of a scheduled hour, may help preserve the distinction between therapeutic use and the beginnings of problematic use.

The biological logic behind the proposal comes from a well-documented phenomenon in behavioral pharmacology known as negative reinforcement. In people who are not addicted, opioid self-administration tracks the presence of pain: the drug is taken because it relieves something aversive, and the relief itself reinforces the behavior. Classic laboratory work supports this coupling. In studies of arthritic rats, opiate self-administration rose and fell with the intensity of chronic nociceptive pain, functioning almost as a readout of the animals’ discomfort. Human experiments point the same way: in healthy volunteers given fentanyl, a cold-water immersion stressor changed the drug’s reinforcing and subjective effects, suggesting that distress and pain modulate how rewarding an opioid feels.

Clinical studies in people with chronic pain echo the pattern. Research by Von Korff and colleagues compared time-scheduled with pain-contingent opioid dosing in chronic opioid therapy and found no clear advantage for fixed schedules, while daily-life monitoring studies have shown that prescription opioid use tends to co-occur with, and lag behind, spikes in pain and negative affect. In other words, in the therapeutic setting, taking the drug when it hurts is the normal, expected behavior, and it is the behavior that addiction neuroscience would predict in people whose brains have not been reshaped by dependence.

The trouble, Davis argues, is that this coupling is not permanent. With chronic use, the link between pain and opioid-taking weakens. Neuroadaptations described by Volkow, Koob, and other addiction researchers, including opponent-process mechanisms, escalating negative affect between doses, and the recruitment of stress and anti-reward circuitry, emerge with regular exposure itself, independent of whether pain is present. Over time, opioid-taking can become progressively pain-independent, driven instead by relief of withdrawal-like states or by conditioned cues. In the framework of Koob’s negative reinforcement model, the drug that once relieved pain now relieves the discomfort of its own absence, a transition that blurs the line between analgesia and addiction.

This matters for oncology because the patient population has changed. Around-the-clock dosing was designed for continuous, severe pain in people with limited life expectancy, when the dominant clinical failure was undertreatment and the risk of long-term dependence was largely moot. Contemporary cancer care produces prolonged survival and chronic treatment-related pain: neuropathy from chemotherapy, postsurgical syndromes, radiation fibrosis, and musculoskeletal sequelae of endocrine therapy. Studies of opioid prescribing among older cancer survivors have raised safety concerns, and the concept of complex persistent opioid dependence, described by Manhapra, Ballantyne, and colleagues, captures the gray zone in which long-term opioid therapy creates dependence that is neither classic addiction nor straightforward analgesia.

The evidence base for scheduled versus as-needed dosing in cancer pain itself is thinner than the doctrine suggests. A systematic review and meta-analysis by Edler-Buggy and colleagues comparing regular with as-needed opioid dosing for chronic cancer pain found no clear superiority of regular dosing on the outcomes examined. Meanwhile, current guidelines from the CDC, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network already endorse principles that align with Davis’s proposal: careful patient selection, risk stratification, monitoring, and attention to whether opioids continue to provide functional benefit. The commentary is therefore largely guideline-concordant, offering a unifying rationale rather than a radical departure.

Davis is explicit about the limits of the framework. Pain-contingency is difficult to measure directly in clinical practice; patients cannot always distinguish pain relief from relief of anxiety or dysphoria, and electronic prescribing records rarely capture the temporal relationship between symptoms and doses. Moreover, because relevant neuroadaptation begins with regular use itself, preserving pain-contingency cannot eliminate risk; it can only serve as a marker and a moderating strategy. The framework also does not oppose around-the-clock dosing for continuous severe cancer pain, where scheduled administration remains appropriate and humane. What it offers is a candidate principle, not a proven intervention, for keeping opioid exposure tethered to symptom relief in the growing population of survivors.

The implications reach beyond oncology. If the coupling between pain and opioid-taking is a behavioral signature that distinguishes therapeutic use from escalation toward addiction, then clinical monitoring could, in principle, watch for its erosion: doses requested well before scheduled intervals without reported pain, use that persists as pain resolves, or escalating consumption unaccompanied by functional improvement. Recent work on avoidance learning in chronic opioid users, reported by Geissler and colleagues in JAMA Psychiatry, adds to the picture that long-term exposure changes decision-making circuitry in measurable ways. Consensus-based guidance for patients with advanced cancer and opioid misuse or use disorder, published by Fitzgerald Jones and colleagues in JAMA Oncology, already emphasizes structured assessment; a pain-contingency lens could sharpen those tools.

None of this diminishes the moral core of the original cancer pain movement, which correctly identified untreated pain as a scourge and scheduled opioids as its remedy. Davis’s reappraisal is best read as an update for a new era: the same drugs that freed dying patients from agony are now dispensed for years to survivors whose pain is chronic, fluctuating, and entangled with the vulnerabilities of long-term exposure. In that setting, the timing of a dose may carry information that the dose itself does not. Keeping opioids linked to pain, whenever clinically feasible, is a modest, testable idea, and one that could help clinicians honor both halves of their duty, relieving suffering while protecting the brain’s capacity to tell the difference between relief and craving.

Subject of Research: Pain-contingent opioid dosing and addiction risk in cancer pain management

Article Title: Pain-contingent opioid use and addiction risk in cancer pain: a reappraisal of around-the-clock dosing

Article References: Davis, M. P. (2026). Pain-contingent opioid use and addiction risk in cancer pain: a reappraisal of around-the-clock dosing. Supportive Care in Cancer, 34(11), Article 1086. https://doi.org/10.1007/s00520-026-11321-6

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11321-6

Keywords: cancer pain, opioid stewardship, around-the-clock dosing, pain-contingent opioid use, addiction, negative reinforcement, cancer survivorship, opioid dependence, palliative care, chronic pain, behavioral pharmacology, clinical guidelines

The study team, led by researchers from Chengdu Xinjin District People’s Hospital and Sichuan Provincial People’s Hospital, enrolled patients diagnosed according to the FIGO 2018 staging criteria who had undergone chemoradiation, chemotherapy alone, radiation alone, targeted therapy, or no anticancer treatment at all. By drawing on electronic medical records alongside structured patient questionnaires, the investigators assembled a detailed picture of each patient’s disease status, treatment history, and symptom profile. Fatigue was assessed using validated multidimensional instruments, allowing the team to distinguish mild exhaustion from the moderate-to-severe syndrome that most interferes with daily functioning. This dual-source data approach matters because fatigue is notoriously underreported in routine oncology visits, often dismissed by both patients and clinicians as an inevitable consequence of cancer treatment rather than a treatable condition in its own right.

When the researchers ran their multivariate logistic regression, seven independent factors emerged as significant predictors of moderate-to-severe fatigue. Disease stage carried a P value of 0.001, meaning that women with more advanced tumors were substantially more likely to report debilitating exhaustion. Performance status, measured on the Eastern Cooperative Oncology Group scale, was also significant at P = 0.003, reflecting the intuitive but clinically important observation that patients already weakened by their illness are more vulnerable to fatigue. Cancer pain, anemia, and poor appetite each showed even stronger associations, all with P values below 0.001, painting a picture of fatigue as a synergistic symptom cluster rather than an isolated complaint. Perhaps most thought-provoking was the finding that proactive clinician attention to fatigue complaints was independently associated with lower rates of severe fatigue, with P = 0.042, suggesting that the quality of supportive care itself shapes patient outcomes.

The biological logic behind these associations is well supported by the broader literature. Advanced tumor burden drives systemic inflammation, releasing cytokines such as tumor necrosis factor that act directly on the central nervous system to produce the sensation of exhaustion. Anemia reduces oxygen delivery to tissues, compounding the physical cost of every activity, while poor appetite accelerates the catabolic spiral of cancer cachexia, a syndrome whose molecular basis has been increasingly mapped in recent years. Pain disrupts sleep and depletes the physical and psychological reserves patients need to cope with treatment. In other words, the Chinese findings align with a mechanistic model in which fatigue is the downstream product of multiple converging physiological insults, each of which represents a potential point of intervention.

The most eye-catching result, however, concerned Buzhong-Yiqi, a classical herbal formula first codified in the Jin-Yuan dynasty treatises on the spleen and stomach, which in Traditional Chinese Medicine theory is thought to tonify qi and address patterns of internal injury. In the raw comparison between patients who received the formula and those who did not, the BZYQ group showed meaningfully lower symptom scores on independent-sample t-tests and Chi-squared comparisons. But observational data of this kind are always vulnerable to confounding: clinicians may simply prescribe the formula to patients who are less sick to begin with, or conversely to those with more resources and better overall care. To address this, the researchers turned to a statistical technique called propensity-score weighting.

Propensity-score weighting is a method borrowed from causal inference that attempts to simulate the balance of a randomized trial using observational data. Each patient receives a score representing the probability, given her measured baseline characteristics, of having been assigned to the BZYQ group. By weighting patients according to the inverse of these probabilities, the technique creates pseudo-populations in which treated and untreated groups are statistically comparable across the measured covariates, allowing the treatment effect estimate to be freed from the distortion introduced by non-random prescribing. After applying this weighting, the association between BZYQ use and fatigue remained robust: patients in the treated group had a 68.3 percent reduction in the odds of moderate-to-severe cancer-related fatigue, corresponding to an odds ratio of 0.317 with a P value below 0.001.

It is crucial to interpret this number with appropriate scientific caution. This was a retrospective, single-region observational study of 144 patients, not a randomized controlled trial, and propensity-score methods can only adjust for confounders that were measured and recorded. Unmeasured factors, such as differences in social support, adherence, nutritional status, or general health consciousness, could still explain part of the observed association. The authors themselves are careful to frame the finding as preliminary evidence, describing the result as real-world observational data that provides clues for further exploration of the formula’s application value in fatigue management rather than proof of efficacy. Previous systematic reviews of Chinese herbal medicine for cancer-related fatigue have noted the scarcity of high-quality randomized trials, making rigorous prospective testing the obvious next step.

Even setting the herbal question aside, the study carries a clear and actionable message for oncology practice. Cancer-related fatigue is recognized in clinical practice guidelines from both the National Comprehensive Cancer Network and the European Society for Medical Oncology as a syndrome deserving systematic screening and management, yet it remains chronically underassessed in busy clinics. The finding that proactive clinician attention independently predicts better fatigue outcomes suggests that simply asking about exhaustion, taking it seriously, and intervening early may itself change the trajectory of the symptom. The authors argue that fatigue screening should be built into routine care for cervical cancer patients, with long-term dynamic assessment throughout diagnosis and treatment rather than a one-time check at the start of therapy.

The modifiable risk factors identified in the study also offer concrete targets. Cancer pain can be addressed with standardized analgesic protocols, anemia can be monitored and corrected where clinically appropriate, and poor appetite can trigger nutritional support before cachexia takes hold. Each of these interventions is grounded in existing supportive-care guidelines, and each plausibly interrupts one of the converging pathways that produce severe fatigue. For a disease like locally advanced cervical cancer, where treatment itself, whether chemoradiation, platinum-based chemotherapy, or newer immunotherapies and anti-angiogenic agents, imposes a heavy physiological toll, the cumulative benefit of aggressively managing these secondary conditions could be substantial for patients’ quality of life.

Cervical cancer remains a major global health challenge, with GLOBOCAN 2022 estimates placing it among the leading causes of cancer incidence and mortality worldwide, and China bearing a significant share of the burden. As survival improves through combined modality therapy and emerging systemic agents, the spotlight is shifting toward survivorship and the long-term symptoms that erode patients’ daily functioning. This study adds to a growing body of work showing that fatigue is not a trivial side effect but a multifactorial syndrome intertwined with tumor biology, treatment toxicity, and the quality of supportive care. Whether Buzhong-Yiqi ultimately earns a place in evidence-based fatigue management will depend on prospective trials, but the message that half of these patients endure moderate-to-severe exhaustion, and that much of it may be preventable, is one that oncology teams everywhere cannot afford to ignore.

Subject of Research: Prevalence, risk factors, and management of moderate-to-severe cancer-related fatigue in locally advanced cervical squamous cell carcinoma, including its association with Buzhong-Yiqi use

Article Title: Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model

Article References: Li, C., Luo, Z., Tian, L., Deng, W., Pang, Q., Bentley, G. T., Luo, Y., & Xie, K. (2026). Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model. Supportive Care in Cancer, 34(11), Article 1084. https://doi.org/10.1007/s00520-026-11335-0

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11335-0

Keywords: cancer-related fatigue, cervical cancer, Buzhong-Yiqi, Traditional Chinese Medicine, propensity-score weighting, supportive care, anemia, cancer pain, ECOG performance status, chemoradiation, quality of life, retrospective study

The study, published in Supportive Care in Cancer, drew on the linked SEER-Medicare database, a powerful resource that merges population-based cancer registry data from the Surveillance, Epidemiology, and End Results program with billing claims from the federal health insurance program that covers most Americans aged sixty-five and older. The research team, led by Olajumoke A. Olateju of the University of Houston’s PREMIER Center with collaborators at Penn State College of Medicine and Sungkyunkwan University, identified 42,931 Medicare beneficiaries diagnosed with breast, colon, or lung cancer and a comparison cohort of 108,218 patients without cancer. All participants were continuously enrolled in Medicare Parts A, B, and D, the components covering hospital care, physician services, and outpatient prescription drugs, and none were enrolled in private Medicare Advantage plans, which would have obscured their prescription records.

To isolate the effect of the guideline, the investigators divided the study window into two periods. The pre-policy period ran from January 2014 through November 2015, capturing prescribing behavior before the recommendations appeared, while the post-policy period spanned April 2016 through September 2017, after clinicians had time to absorb and react to the new guidance. The three-month gap between the periods deliberately excluded the transition months when the guideline was being publicized. For each patient, the researchers measured opioid use within three months of a cancer diagnosis or an index insurance claim, tracking four distinct outcomes: the monthly rate of opioid prescribing, the monthly number of days of opioid supply, the average daily dose expressed in morphine milligram equivalents, or MME, and the frequency of high-risk co-prescribing with benzodiazepines, antidepressants, or non-benzodiazepine sedatives.

The statistical engine behind the analysis was a difference-in-differences design, a technique borrowed from health economics that compares how each group’s outcomes changed over time and then subtracts the change in the comparison group from the change in the group of interest. Because both groups experienced the same broad cultural and regulatory shifts during the study years, this approach filters out secular trends and isolates the differential impact of the guideline on cancer patients relative to everyone else. The models adjusted for baseline characteristics such as age, sex, race, comorbidities, and prior medication use, strengthening the case that the observed gaps reflect genuine differences in how the guideline was applied rather than pre-existing disparities between the cohorts.

The headline finding is striking in its asymmetry. After the guideline took effect, opioid prescribing declined in both groups, but the decline was far steeper among patients without cancer, while changes among cancer patients were minimal. The difference-in-difference estimates quantified that divergence precisely: cancer patients experienced reductions that were 0.14 percentage points smaller per month in opioid prescribing rates than their non-cancer counterparts, a difference that was highly statistically significant, and their monthly days of opioid supply fell 3.07 days less than the comparison group. In practical terms, the prescribing pullback that swept through general pain medicine largely bypassed oncology practices caring for newly diagnosed older adults.

Not every measure moved the same way, however. The average daily dose in morphine milligram equivalents did not change significantly differently between the groups, with a point estimate of 16.73 MME and a confidence interval stretching from minus 43.36 to 76.82, a result the authors report with a p-value of 0.5853. That null finding suggests that when clinicians did prescribe opioids for cancer-related pain, the intensity of those prescriptions, measured in potency per day, remained essentially stable across the policy transition. The guideline’s influence, in other words, showed up in whether and how long opioids were dispensed rather than in how strong the daily doses were for those who received them.

The co-prescribing results carry perhaps the most important safety implications. Combining opioids with benzodiazepines, the sedative class that includes drugs such as alprazolam and lorazepam, is well documented to elevate overdose risk, because both drug types depress the central nervous system and can synergistically suppress breathing. The Food and Drug Administration has issued its strongest boxed warning about the combination, and Medicare administrators have flagged concurrent opioid-benzodiazepine use as a quality concern. High-risk co-prescribing declined overall in the study population after the guideline, consistent with a broader national push to reduce these combinations. Yet here again the reductions were smaller among cancer patients: opioid-benzodiazepine, opioid-antidepressant, and opioid-non-benzodiazepine sedative combinations all decreased less in the cancer cohort, with p-values below 0.0001 for each comparison.

Why would cancer patients be relatively insulated from the guideline’s effects? The most likely explanation is intentional. The 2016 guideline was explicitly framed as applying to chronic pain outside of cancer care, palliative care, and end-of-life settings, and oncology societies such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network maintain separate pain management frameworks that recognize cancer pain as a distinct clinical entity. Pain is extraordinarily common in cancer, affecting a majority of patients across the disease trajectory, and undertreated cancer pain remains a persistent problem associated with suffering, functional decline, and stigma that patients themselves report as a barrier to adequate relief. Clinicians caring for these patients appear to have heeded the carve-out, continuing to prescribe when the clinical situation demanded it.

But the persistence of high-risk co-prescribing among older cancer patients is not automatically reassuring. Older adults are particularly vulnerable to the sedative burden of combined medications, with elevated risks of falls, fractures, cognitive impairment, and respiratory depression. Antidepressants and benzodiazepines are frequently prescribed in this population for legitimate reasons, including depression, anxiety, neuropathic pain, and sleep disturbance, all of which are common complications of cancer and its treatment. The finding that these combinations declined less among cancer patients could reflect appropriate clinical prioritization of symptom control, or it could signal a blind spot in medication safety review for a group whose many prescriptions are managed by multiple specialists. Disentangling those two possibilities is a task the claims data used in this study cannot fully accomplish.

The study arrives at a moment when the pendulum of opioid policy is swinging again. The CDC issued a revised clinical practice guideline in 2022 that softened some of the 2016 recommendations and emphasized that opioids remain appropriate for many patients with serious illness, partly in response to reports of patients with legitimate pain being cut off abruptly. This new evidence from SEER-Medicare suggests that, at least among older adults with common cancers, the feared collateral damage of the 2016 guideline on cancer pain treatment did not materialize in prescribing patterns, while the intended safety improvements did reach the broader population. The challenge ahead, the authors’ work implies, is to preserve that distinction while extending medication safety scrutiny, particularly around sedative co-prescribing, to the cancer population without reigniting the undertreatment fears that have shadowed cancer pain management for decades. As opioid stewardship programs mature across hospitals and oncology practices, data like these will be essential for calibrating policies that protect patients from both overdose risk and unrelieved pain.

Subject of Research: Changes in opioid prescribing and high-risk co-prescribing among older Medicare beneficiaries with and without cancer following the 2016 CDC opioid guideline

Article Title: Changes in opioid prescribing and high-risk co-prescribing after implementation of the 2016 CDC opioid guideline among older adults with and without cancer

Article References: Olateju, O. A., Byun, J.-Y., Okeke, C. M., Shen, C., & Thornton, J. D. (2026). Changes in opioid prescribing and high-risk co-prescribing after implementation of the 2016 CDC opioid guideline among older adults with and without cancer. Supportive Care in Cancer, 34(11), Article 1076. https://doi.org/10.1007/s00520-026-11273-x

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11273-x

Keywords: opioid prescribing, CDC opioid guideline, cancer pain, SEER-Medicare, benzodiazepines, co-prescribing, older adults, health policy, morphine milligram equivalents, supportive care, medication safety, difference-in-differences

Rapid intravenous opioid titration is a deceptively simple concept. Rather than waiting hours for oral medications to take effect, clinicians administer small intravenous boluses of an opioid — typically morphine — every two minutes, reassessing the patient’s symptoms and side effects after each dose. The process continues until adequate relief is achieved, a clinically relevant adverse event appears, or further dose escalation yields no benefit. International guidelines from ESMO, ASCO, and the European Association for Palliative Care recommend opioids for severe cancer pain and dyspnea, but the evidence base for the rapid titration variant has remained thin, drawn largely from small single-center cohorts. The CHUV team set out to describe how the technique actually works in routine practice.

The retrospective observational study included 38 consecutive adult inpatients who underwent rapid intravenous opioid titration for an acute severe pain or dyspnea crisis between April 2024 and February 2026. All patients had cancer, with 68 percent presenting with stage IV disease, and the most frequent primary tumors were upper gastrointestinal, urogenital, and lung cancers. The median age was 63 years, and the median Charlson Comorbidity Index was 8, reflecting a heavily burdened patient population. Crucially, 87 percent of patients were already receiving baseline opioid therapy, predominantly oral morphine at a median dose of 80 milligrams per day in oral morphine equivalents — meaning most titrations were not starting from scratch but recalibrating existing therapy in the face of a sudden crisis.

The technical details of the titration procedure reveal how individualized the approach is. For patients already on opioids, clinicians generally used the same molecule intravenously, deriving the initial bolus from the patient’s baseline regimen. Opioid-naive patients typically started with low-dose intravenous morphine. The median initial dose was just 5 milligrams in intravenous morphine equivalents, and patients required a median of only 3 boluses to reach symptom control. The median cumulative opioid exposure was 12 milligrams IME, and the median titration duration was a strikingly short 8 minutes. Every bolus was administered under close bedside supervision by palliative care physicians and nursing staff, with symptom intensity and tolerability reassessed continuously throughout.

The results were dramatic. Among the 34 patients treated primarily for pain, median pain intensity on the Numerical Rating Scale fell from 8 to 2, a median reduction of 5 points, with a p-value below 0.001. Ninety percent of all patients met the predefined responder criteria — a reduction of at least 2 points on the pain scale or an improvement of at least one category on the Verbal Descriptor Scale used for breathlessness. All four patients treated for dyspnea improved, shifting from predominantly severe breathlessness at baseline to predominantly mild dyspnea afterward. Titration was successfully completed in 82 percent of patients, with the remaining cases split between four discontinuations due to adverse events and three due to insufficient symptom relief.

Tolerability data were equally encouraging, though nuanced. Some form of adverse event occurred in 39 percent of patients, but the vast majority were mild, grade 1 events. The most common were somnolence, affecting 26 percent of patients, and dizziness, affecting 11 percent. Only one patient experienced a grade 3 event — severe somnolence that resolved with observation alone. Clinically relevant adverse events, defined as grade 2 or higher or any event forcing premature discontinuation, occurred in just 4 patients, or 11 percent of the cohort. Notably, despite the high prevalence of pre-existing opioid exposure and the speed of dose escalation, the cumulative opioid doses remained modest, suggesting that the technique achieves control with less drug than clinicians might fear.

Perhaps the most patient-centered finding came at the 24-hour mark: 76 percent of patients reported complete satisfaction with their symptom management when directly questioned during routine clinical assessment. The statistical analysis revealed a clear pattern behind those numbers. Patients who reported complete satisfaction had experienced greater symptom improvement, with a median NRS change of 5 points compared with 2 points among those only partially satisfied or unsatisfied, a difference that reached statistical significance. Conversely, patients who suffered clinically relevant adverse events reported significantly lower satisfaction. The message, the authors suggest, is that efficacy and tolerability must be balanced in real time — both shape how patients remember their care.

The findings align with a small but consistent body of prior work. Earlier studies using intravenous morphine or oxycodone in advanced cancer patients have similarly reported meaningful pain relief within minutes and low rates of significant toxicity. What distinguishes the CHUV study is its grounding in unselected daily practice rather than a protocolized research setting. Because the data reflect what actually happened when specialist palliative physicians reached for this tool at the bedside, they provide a realistic picture of feasibility — how many boluses are truly needed, how long titration takes, and how often things go wrong when the technique is deployed under ordinary clinical pressures.

The authors are careful to enumerate the study’s limitations, and they matter. The retrospective design introduces potential selection and information bias. The sample was small, particularly for dyspnea, where only four patients were treated, limiting statistical power. The single tertiary center setting may restrict generalizability, and the absence of a standardized titration protocol — while faithful to real-world practice — introduces variability. As an observational study, placebo effects cannot be excluded. Adverse events were systematically assessed only during titration and for 20 minutes afterward, so delayed opioid toxicity, including delirium occurring later, may have gone undetected. Satisfaction measured at 24 hours also cannot be attributed exclusively to the titration, since subsequent changes to baseline opioid regimens were not systematically collected. And because every patient had cancer, extrapolation to non-malignant serious illness should be cautious.

Even with those caveats, the study delivers a compelling real-world signal: rapid intravenous opioid titration, performed under close specialist supervision, was associated with substantial and fast symptom improvement, high patient-reported satisfaction, and a low rate of clinically relevant adverse events during the monitored window. The authors argue that further prospective studies are warranted to define optimal use and longer-term safety, while acknowledging that placebo-controlled trials in patients experiencing severe pain or breathlessness raise serious ethical concerns and may prove difficult to conduct. For now, the message for palliative care teams is that an eight-minute, three-bolus intervention — delivered with vigilance — may be one of the most efficient ways to pull a dying patient back from the edge of an unbearable crisis.

Subject of Research: Rapid intravenous opioid titration for acute pain and dyspnea crises in palliative care

Article Title: Rapid intravenous opioid titration for acute symptom crises in palliative care: a real-world retrospective study

Article References: Nasrinfar, K., Simonet, V., Trippini, A., Bosia, T., Bruera, E., & Gamondi, C. (2026). Rapid intravenous opioid titration for acute symptom crises in palliative care: a real-world retrospective study. Supportive Care in Cancer, 34(10), Article 1010. https://doi.org/10.1007/s00520-026-11245-1

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11245-1

Keywords: palliative care, opioids, intravenous titration, cancer pain, dyspnea, morphine, symptom crisis, patient satisfaction, adverse events, palliative medicine, real-world study, Lausanne University Hospital

The mechanistic case against opioids is, on its own terms, coherent and reproducible. Mu-opioid receptors, the molecular docking sites targeted by morphine and related drugs, are expressed not only on neurons but also on key cells of the immune system, including natural killer cells and CD8-positive T lymphocytes, the two cell types most responsible for recognizing and destroying tumor cells. In vitro experiments and animal models have repeatedly shown that activating these receptors can dampen the cytotoxic activity of NK cells, impair T-cell proliferation and function, and dysregulate the cytokine signaling networks that coordinate an immune response. Opioids can also act centrally, engaging the hypothalamic-pituitary-adrenal axis and the sympathoadrenal system to raise levels of cortisol and catecholamines, stress hormones that are themselves immunosuppressive. In animal studies, these effects have sometimes translated into faster tumor growth or greater metastatic spread.

The problem, Mercadante argues, is the gap between the petri dish and the clinic. When researchers move from controlled animal experiments to human studies, the evidence base changes character entirely. Clinical data on opioids and cancer outcomes come almost exclusively from retrospective cohort analyses, in which investigators look back at existing patient records rather than randomly assigning treatment. Such studies are notoriously vulnerable to a statistical trap known as confounding by indication. Patients who require strong opioids are, almost by definition, those with more advanced disease, larger tumor burdens, worse performance status, and greater systemic inflammation. Each of those factors independently predicts poorer survival and weaker responses to immunotherapy, regardless of what painkillers the patient happens to receive. The opioid, in other words, may simply be a marker of how sick someone is, not a cause of it.

That confounding problem becomes even sharper when the outcome in question is response to immune checkpoint inhibitors, the antibody drugs that unleash T cells against tumors by blocking inhibitory receptors such as PD-1 and PD-L1. Several retrospective analyses and at least one systematic review and meta-analysis have reported that cancer patients taking opioids fare worse on checkpoint inhibitors than those who are not. But the same logic applies: patients needing opioids for breakthrough pain are more likely to have bulky, symptomatic, late-stage disease, and it is the disease, not necessarily the drug, that drives the inferior outcomes. Without pain-matched comparators, patients with equally advanced cancer but comparable pain control achieved without opioids, the analyses cannot disentangle pharmacology from disease severity.

Mercadante also spotlights a counter-argument that he describes as largely neglected in the literature: uncontrolled cancer pain is itself a potent immunosuppressant. Severe pain activates the same HPA-axis and sympathoadrenal stress pathways that opioids can engage, flooding the body with cortisol and catecholamines that suppress NK cell activity and T-cell function. Pain is not merely a symptom to be tolerated for the sake of immune health; it is an active physiological insult. Systematic reviews have shown that pain severity independently predicts shorter survival in cancer patients, and recent work in older adults with newly diagnosed cancer has linked patient-reported pain severity to reduced survival. In this light, inferior outcomes among opioid users may reflect the disease burden and pain intensity that necessitated opioid therapy in the first place, rather than a direct pharmacological effect of the drugs.

The clinical literature on opioids and infection risk tells a similarly ambiguous story. Some observational studies in patients with cancer pain have examined whether morphine or oxycodone administration correlates with the development of infections, but the findings are inconsistent and suffer from the same confounding by indication. Immunocompromised, advanced-stage patients are more likely to need high-dose opioids and are also more likely to develop infections, making it impossible to attribute causality from retrospective data. Meanwhile, laboratory work continues to show that different opioids do not share identical immunomodulatory properties; some agents appear more immunosuppressive than others in vitro, and genetic factors may modify individual responses. These nuances, while scientifically interesting, have not yet produced a clinically actionable rule for prescribing.

One intriguing line of evidence has come from studies of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist used to treat opioid-induced constipation. A retrospective analysis of patients with advanced cancer suggested that treatment with methylnaltrexone was associated with increased survival, raising speculation that blocking peripheral opioid receptors might unleash antitumor immunity. But this observation, too, comes from uncontrolled data, and alternative explanations, including healthier patients tolerating the drug better, have not been excluded. Network-based computational analyses have also suggested that opioids and checkpoint inhibitors differentially regulate overlapping immune signaling pathways in tumors such as triple-negative breast cancer, providing a plausible molecular framework for interaction but not proof of clinical harm.

Weighing the totality of the evidence, the review concludes that the preclinical signal of opioid immunosuppression, while real and mechanistically coherent, has not been validated in clinical studies of sufficient quality to justify withholding or limiting opioid analgesia in cancer patients. This includes patients receiving immune checkpoint inhibitors, a population in whom clinicians might be especially tempted to minimize opioid exposure out of fear of compromising immunotherapy. Current guidelines from bodies such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology already establish effective pain management as a clinical priority in cancer care, and the new analysis reinforces that stance: the known harms of unrelieved pain, physiological, psychological, and prognostic, far outweigh a theoretical immunological risk supported only by confounded retrospective data.

The path forward, according to the review, is not practice change but better research. Prospective studies designed with pain-matched comparators are needed, in which patients with equivalent cancer stages and equivalent pain intensity are compared across different analgesic strategies, including opioid-free regimens where feasible. Such designs would finally allow investigators to separate the pharmacological effects of opioids from the effects of the disease and the pain they treat. Until those studies are done, the review’s message to oncologists, palliative care specialists, and patients is straightforward: cancer pain should be treated effectively, opioids should not be withheld out of immunological fear, and the question of whether these drugs subtly shape tumor immunity remains an open scientific question rather than a settled clinical danger.

The broader significance of the analysis lies in its methodological honesty. In an era when immunotherapy has transformed outcomes in melanoma, lung cancer, and many other malignancies, every drug a patient takes is now scrutinized for possible immune interactions, and opioids, taken by millions of people with cancer worldwide, are a natural target of that scrutiny. But the review serves as a reminder that association is not causation, that the sickest patients receive the most treatments, and that a laboratory mechanism demonstrated in mice and cell cultures does not automatically translate into a bedside mandate. For now, the evidence says the most immunosuppressive thing a clinician can do for a patient in severe cancer pain is to leave that pain untreated.

Subject of Research: The immunosuppressive effects of opioids in cancer pain management and their potential interaction with antitumor immunity and immunotherapy

Article Title: Opioids and immunosuppression in patients with cancer

Article References: Mercadante, S. (2026). Opioids and immunosuppression in patients with cancer. Supportive Care in Cancer, 34(10), Article 1031. https://doi.org/10.1007/s00520-026-11279-5

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11279-5

Keywords: opioids, immunosuppression, cancer pain, morphine, immune checkpoint inhibitors, natural killer cells, T cells, confounding by indication, HPA axis, immunotherapy, palliative care, Supportive Care in Cancer

The scale of the problem the guideline addresses is striking. According to a 2022 systematic review cited in the document, the overall prevalence of pain among cancer patients reaches 44.5 percent, with 30.6 percent experiencing moderate to severe pain. The incidence climbs to roughly 50.3 percent during active treatment, 35.8 percent after effective treatment, and 54.6 percent in advanced, metastatic, or end-stage disease. Under the International Classification of Diseases, 11th Revision, chronic cancer-related pain is formally defined as chronic pain caused by the primary tumor itself or by metastasis, encompassing both chronic cancer pain and chronic post-cancer treatment pain. Because pain profoundly affects physical, psychological, and social functioning, the guideline’s authors argue that its management is an integral component of comprehensive cancer treatment and can even influence survival outcomes.

At the heart of the guideline is the principle of holistic integrative medicine, a philosophy that transforms traditional multidisciplinary team approaches, known as MDT, into a fully integrated care model the authors call MDT-to-HIM. Rather than treating pain as an isolated symptom, this model assembles oncologists, palliative care specialists, pain physicians, surgeons, pharmacists, rehabilitation experts, nutritionists, traditional Chinese medicine practitioners, psychologists, and nurses into a dynamic, patient-centered team. The guideline recommends this collaborative model for patients whose pain is poorly controlled by drug therapy alone, those with intolerable adverse drug reactions, patients with bone metastasis-related pain, and those whose pain coexists with tumor-related complications such as malnutrition, gastrointestinal obstruction, or malignant intracranial hypertension.

Accurate assessment is positioned as the mandatory first step. The guideline prescribes ‘holistic’ and ‘routine, quantitative, and dynamic’ evaluation, recommending the Numerical Rating Scale and the Faces Pain Rating Scale for universal screening, while offering the Behavioral Pain Scale and the Critical Care Pain Observation Tool for patients who cannot self-report, such as those with cognitive impairment or at the end of life. Diagnosis should follow the ICD-11 hierarchical classification, distinguishing nociceptive pain, which affects roughly 59 percent of cancer patients, from neuropathic pain at about 19 percent, and mixed pain at about 20 percent. Nociceptive pain is further divided into somatic and visceral subtypes, each with distinct treatment implications. The guideline also formally defines the concept of a ‘pain crisis’ as new-onset or severe pain arising on a background of stable control, requiring immediate intervention.

Pharmacotherapy remains the backbone of cancer pain management, and the guideline notes that more than 80 percent of patients can achieve good relief through drugs alone. First-line regimens center on opioids, nonsteroidal anti-inflammatory drugs, and adjuvant analgesics such as calcium channel modulators and antidepressants. Notably, the document endorses pharmacogenomic testing, particularly CYP2D6 genotyping, to individualize prodrug therapy like codeine and avoid both poor efficacy and serious adverse reactions. For moderate pain, the guideline suggests that low-dose strong opioids may actually be preferable to weak opioids, given their lower nausea rates, lower cost, and comparable efficacy, though weak opioids carry a well-known ceiling effect. Acetaminophen in combination preparations should not exceed 2 grams daily because of hepatotoxicity risk.

Detailed dosing protocols form a major strength of the document. For opioid-naive patients, titration typically begins with 5 to 15 milligrams of oral morphine or an equivalent short-acting opioid, while opioid-tolerant patients start at 10 to 20 percent of their previous 24-hour total dose. Once stable control is achieved, patients convert to long-acting formulations with a rescue dose of short-acting opioid set at 10 to 20 percent of the daily total for breakthrough pain. Dose increases during maintenance follow pain intensity, ranging from 25 to 50 percent for mild pain up to 75 to 100 percent for severe pain measured on the numerical scale. The guideline also provides granular instructions for opioid rotation, noting that 20 to 44 percent of patients require a switch and that 40 to 80 percent improve analgesia afterward, with methadone conversions demanding reductions of 75 to 90 percent and, ideally, in-hospital supervision.

Safety receives extensive attention. The guideline catalogs management strategies for opioid-induced constipation, nausea and vomiting, pruritus, delirium, urinary retention, sedation, and respiratory depression, including precise naloxone dosing of 1 to 2 milliliters of a 0.4 milligram per 10 milliliter solution when respiratory rates fall below 8 breaths per minute. It also confronts the growing challenge of opioid misuse: prevalence estimates among long-term users range from 21 to 29 percent, and 8 to 12 percent of cancer patients on long-term opioids develop opioid use disorder. The document recommends validated screening tools such as the SOAPP-R and Opioid Risk Tool before initiating therapy, real-time monitoring with the Current Opioid Misuse Measure during treatment, urine drug testing, and prescription drug monitoring programs as pillars of risk mitigation.

When drugs fall short, the guideline opens the door to an arsenal of minimally invasive techniques that can be deployed before, during, or after standard three-step drug therapy. Patient-controlled analgesia via intravenous or subcutaneous routes offers rapid, individualized titration and can even be managed safely at home. Nerve blocks and neurolysis, particularly celiac plexus neurolysis with 75 to 100 percent ethanol, provide durable relief for refractory visceral pain. Percutaneous vertebroplasty stabilizes painful vertebral metastases, while spinal cord and peripheral nerve stimulation offer reversible neuromodulation for stable-tumor neuropathic pain. Perhaps most remarkable is intrathecal drug delivery, in which morphine infused directly into the cerebrospinal fluid is roughly 100 times more potent than the intravenous route and 300 times more potent than oral administration, dramatically reducing systemic doses and their side effects.

The guideline also integrates palliative antitumor therapies as analgesic tools, noting that a single 8-gray dose of radiotherapy relieves bone metastasis pain in about 40 percent of patients, while microwave and radiofrequency ablation can inactivate tumor tissue and reduce pain indirectly. Adjunctive approaches including traditional Chinese medicine, physical therapy, and structured psychological support such as mindfulness-based cognitive therapy and pain neuroscience education round out the multimodal framework. Ultimately, the authors identify the chief barriers to better care as outdated clinical concepts, restricted opioid access, nonstandard treatment, and weak multidisciplinary collaboration, and they express confidence that disseminating this guideline will extend both the quality of life and the survival of patients with cancer pain across China and beyond.

Subject of Research: Clinical practice guideline for the multidisciplinary management of adult cancer pain developed by the China Anti-Cancer Association

Article Title: CACA guidelines for the management of adult cancer pain

Article References: Jin, Y., Zhang, J., Suo, J., Yu, H., Song, L., Chen, F., Cheng, W., Cui, W., Fan, B., Feng, Z., Gong, L., Gu, N., Guo, L., Jia, Y., Li, S., Lin, F., Lin, R., Liu, B., Lu, G., … Xie, G. (2026). CACA guidelines for the management of adult cancer pain. Holistic Integrative Oncology, 5(1), Article 66. https://doi.org/10.1007/s44178-026-00286-5

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00286-5

Keywords: cancer pain, CACA guideline, opioid therapy, palliative care, intrathecal drug delivery, multidisciplinary team, holistic integrative medicine, breakthrough pain, bone metastasis, neuropathic pain, opioid rotation, patient-controlled analgesia

The review identifies three core challenges that have defined traditional pain management for decades. First, assessment depends on patients describing their own suffering, a process vulnerable to emotional state, cultural background and cognitive function, and effectively unusable for infants, dementia patients, the critically ill and postoperative patients who cannot self-report. Second, conventional imaging lacks the sensitivity to detect many pain-related structural changes: plain X-rays miss early osteoarthritis and soft tissue lesions, while MRI, despite excellent soft tissue resolution, struggles with functional pain and is expensive and time-consuming. Third, treatment selection relies on clinical experience and guidelines without individualized prediction, leaving roughly 30 to 40 percent of patients failing to respond adequately to their initial regimen. The result is prolonged suffering, repeated medication adjustments, rising costs and heightened risk of adverse drug reactions. Deep learning, the authors contend, offers an end-to-end pathway from symptom identification to mechanism analysis, extracting latent pain biomarkers from multi-source heterogeneous data.

The most technically rich portion of the review concerns objective pain assessment, where deep neural networks are being trained to quantify suffering from signals that patients cannot suppress. Computer vision models analyze facial micro-expressions such as frowning and squinting; speech systems capture changes in vocal tone, pitch jitter and spectral energy; and physiological pipelines integrate electroencephalography, skin conductance, heart rate variability and respiration. The performance figures are striking. A neonatal convolutional neural network recognizing pain from infant facial expressions achieved 91 percent accuracy with an area under the curve of 0.93, while a three-branch network analyzing newborn cries reached 96.77 percent accuracy in binary classification, using only about 2.6 percent of the parameters of VGG16. In adults, a spatial-temporal attention LSTM network classified postoperative pain into three levels from facial landmarks with 86.6 percent accuracy, and an autoencoder-LSTM model fused motion capture with surface electromyography to detect protective behaviors, improving over single-modality baselines by 38.5 percent.

Physiological signals have proven equally fertile ground. A framework called PainAttnNet, built on transformer architectures with multiscale feature extraction, classified pain intensity from electrodermal activity with 85.56 percent accuracy on the BioVid dataset. A dual-branch spatiotemporal model processing scalp EEG in children distinguished pain from non-pain states with 87.83 percent accuracy, and, notably, visualization of electrode contributions showed that accuracy remained at 84 percent even when only nine electrodes were retained, a finding that could dramatically simplify data collection in pediatric settings. A hybrid BiLSTM-support vector machine pipeline classified postoperative pain intensity from electrocardiographic signals at 84.14 percent validation accuracy, while bidirectional LSTMs applied to functional near-infrared spectroscopy achieved 90.6 percent accuracy across four pain intensity categories, outperforming unidirectional variants by 5 to 8.4 percentage points. Resting-state frontal EEG biomarkers have likewise been proposed for grading chronic neuropathic pain severity, moving the field closer to objective clinical translation.

Multimodal fusion, however, emerges as both the field’s greatest promise and its most sobering cautionary tale. Because any single signal can be lost in real clinical environments, obscured by oxygen masks, sedation, motion artifacts or equipment failure, fusing facial, vocal and physiological streams offers redundancy and robustness. In neonatal postoperative pain assessment, a decision-level voting fusion of facial expressions, body movements and crying maintained strong performance even when a quarter of each modality’s data was randomly removed, with the fused area under the curve of 0.868 clearly surpassing the best single modality at 0.774. Yet the review is candid that fusion is not a universal win: in real postoperative wards, single-modality models, particularly those using respiratory rate at 88.24 percent balanced accuracy, consistently outperformed multimodal fusion, which was degraded by motion artifacts, asynchronous acquisition and environmental noise rarely encountered in laboratory datasets. The authors call for cross-modal pretraining, medical knowledge graphs and event-driven fusion strategies to close this gap.

The second pillar of the review concerns intelligent structural identification, where convolutional and transformer-based models automatically segment the anatomical landscape of pain. Deep learning systems now detect lumbar spondylolisthesis from X-rays, quantify vertebral fractures through anchor-free keypoint detection with expert-level localization error of 0.92 millimeters and an AUC of 0.96, and grade intervertebral disc degeneration from MRI in real time using YOLOv5 architectures with over 95 percent classification accuracy. On the cervical spine, where vertebral similarity and complex anatomy make segmentation notoriously difficult, a 2D U-Net framework with superior-inferior labeling achieved Dice coefficients above 94 percent even on pathological data, and a transformer-based model reduced radiologist interpretation time for degenerative cervical MRI from up to 490 seconds to as little as 90 seconds, with the greatest benefit accruing to residents.

Nerve and needle localization extend this vision into interventional precision. Mask R-CNN-based systems segment the median nerve at the carpal tunnel from ultrasound without manual region selection, while U-Net variants track the vagus nerve in real time with over 90 percent recognition accuracy even in low-quality images, trained from mere bounding-box annotations. The dorsal root ganglion, a structure implicated in neuropathic pain but historically too small to segment automatically, has now been delineated in MRI using a meta-optimized nnU-Net framework, revealing genotype-related volume changes in a Fabry disease model. For ultrasound-guided nerve blocks, deep networks locate needle tips that are frequently invisible at steep angles: time-aware LSTMs combined with dynamic background subtraction recover weak tip echoes, and an optical-flow-enhanced YOLO variant tracks speckle dynamics of entirely invisible needles while cutting model parameters by 98 percent for real-time deployment, reaching sub-millimeter localization accuracy in robotic settings.

The third pillar maps AI onto specific pain conditions. For shoulder disorders, multimodal models fusing X-rays with clinical data rule out rotator cuff tears with 97.3 percent sensitivity, and 3D networks trained on more than 11,000 MRI studies classify full-thickness tears with AUCs as high as 0.99, outperforming experienced radiologists. In osteoarthritis, deep stacked ensembles grade knee severity at up to 99.71 percent accuracy, automated systems measure hip-knee-ankle angles 126.7 times faster than manual workflows, and a model called DeepKOA predicts structural and symptomatic progression over 24 to 48 months from multimodal MRI. Multiomic deep clustering has even identified three molecular subtypes of knee osteoarthritis that predict post-arthroplasty pain outcomes with AUCs of 0.84 to 0.88. For trigeminal neuralgia, machine learning on brain morphology predicted gamma knife surgery efficacy with 96.7 percent accuracy, and radiomics models now identify which patients will achieve durable relief from percutaneous balloon compression, lifting three-year pain-free survival in favorable subgroups from 51.1 percent to 86.4 percent. Machine learning models predicting postherpetic neuralgia from 23,326 real-world electronic health records, and LSTM networks forecasting cancer pain exacerbations hours before onset, illustrate the shift toward preemptive intervention.

The review closes with a bracing reality check. Most studies remain small, single-center and internally validated; when tested externally, performance routinely collapses, as when a sacroiliitis model’s sensitivity plummeted from near-expert levels to 56 percent. Data imbalance, annotation inconsistency, demographic bias and unmodeled anatomical variation pervade the literature, and explainable AI outputs often misalign with what clinicians actually need. Privacy risks from biometric pain data, unresolved liability frameworks, absent reimbursement mechanisms and the economic burden of deployment all stand between laboratory success and bedside reality. The authors argue that pain AI must now pivot from a method-driven race for benchmark accuracy to an evaluation-driven, utility-driven paradigm in which human-AI collaboration, longitudinal outcomes and patient-centered benefit define success. If that transition succeeds, the era in which suffering could only be described, rather than measured, understood and preempted, may finally be drawing to a close.

Subject of Research: Artificial intelligence applications in objective pain assessment, medical image analysis and treatment decision-making for chronic pain conditions

Article Title: Current state of research and future developments of artificial intelligence in pain diagnosis and treatment

Article References: Yang, Z., Li, L., Bo, S., Zhong, J., & Zhang, Y. (2026). Current state of research and future developments of artificial intelligence in pain diagnosis and treatment. Journal of Translational Medicine, 24(1), Article 1177. https://doi.org/10.1186/s12967-026-08529-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08529-9

Keywords: artificial intelligence, chronic pain, deep learning, pain assessment, multimodal data fusion, medical imaging, trigeminal neuralgia, osteoarthritis, postherpetic neuralgia, cancer pain, explainable AI, precision medicine